Back to Search

Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure

Metairie, Louisiana, 70006
Dayton, Ohio, 45414
Hadar, Nebraska, 68701
Binghamton, New York, 13901
Durham, North Carolina, 27710
Search open until 03/31/2023

This clinical study will assess the safety and immunogenicity of 2 dose levels of mRNA-1653, a combined human metapneumovirus and human parainfluenza virus type 3 vaccine, in healthy adults (18 to 49 years of age) and 2 dose levels in children (12 to 59 months of age) with serologic evidence of prior exposure. The safety profile of the adult cohort will permit enrollment of the pediatric cohort.


Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, learn about Clinical

Ages Eligible for Study Min Age: 12 Months - Max Age: 49 Years
Sexes Eligible for Study All
Accepts Healthy Volunteers Yes

Visit ClinicalTrials.Gov for more information
Support nonprofit organizations through participating in clinical trials at no cost to you
You may also be interested in
Hollywood, Florida and more
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-Year-Old Healthy Adults
Epstein-Barr Virus Infection Read more
Tuscaloosa, Alabama and more
Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Neurobehavioral Disinhibition Including Aggression, Agitation, and Irritability in Patients With Traumatic Brain Injury
Neurobehavioral Disinhibition Read more
New Orleans, Louisiana and more
Evaluation of ADG20 for the Prevention of COVID-19
COVID-19 Read more